Latest news

Arquer Diagnostics @ArquerDx 4 days ago
SYNLAB UK is now able to offer #ADXBLADDER as part of their diagnostic portfolio. #Urologists interested in this service can contact today.
Arquer Diagnostics @ArquerDx 16 days ago
At Arquer, we are honoured to have worked with so many of the #hospitals that are featured in Newsweek's #WorldsBestHospitals2020. We are extremely proud of everything we have accomplished alongside these institutions and look forward to working with more of them in the future.
Arquer Diagnostics @ArquerDx 25 days ago
Monitoring #patients who have successfully undergone treatment for #bladdercancer is of crucial importance. #ADXBLADDER can add a new accuracy to these routine follow-up procedures, making the detection of bladder cancer recurrence easier than ever before.
1 2
Arquer Diagnostics @ArquerDx 35 days ago
With 99% NPV and a very high sensitivity in high-grade tumors, #ADXBLADDER can outperform #cytology and eliminate the need for #bladdercancer patients to undergo multiple #cystoscopies during follow-up procedures. Read more about this on our latest blog:
1 1
Arquer Diagnostics @ArquerDx 44 days ago
#ADXPROSTATE, our test for #prostatecancer, is currently undergoing clinical trials. It's with this product that we hope to simplify and speed up #diagnosis of this form of cancer, improving the outcomes of those affected by this condition across the globe.

Arquer Diagnostics Announces Exclusive Agreement with SYNLAB to Accelerate the Introduction in the UK of Game-Changing non-invasive Diagnostic test for Patients with Suspected Bladder Cancer

Sunderland, United Kingdom, 13th July 2020 – Arquer Diagnostics, a UK-based company committed to manufacturing and marketing innovative, non-invasive tests for diagnosing and monitoring cancer, today announced that it has entered into an exclusive agreement with SYNLAB UK & Ireland, a leading medical diagnostic services provider.  

Read more…